Cargando…
Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity
Posttranslational modification with SUMO is known to regulate the activity of transcription factors, but how SUMOylation of individual proteins might influence immunity is largely unexplored. The NFAT transcription factors play an essential role in antigen receptor-mediated gene regulation. SUMOylat...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953626/ https://www.ncbi.nlm.nih.gov/pubmed/32986812 http://dx.doi.org/10.1084/jem.20181853 |
_version_ | 1783663952967761920 |
---|---|
author | Xiao, Yin Qureischi, Musga Dietz, Lena Vaeth, Martin Vallabhapurapu, Subrahmanya D. Klein-Hessling, Stefan Klein, Matthias Liang, Chunguang König, Anika Serfling, Edgar Mottok, Anja Bopp, Tobias Rosenwald, Andreas Buttmann, Mathias Berberich, Ingolf Beilhack, Andreas Berberich-Siebelt, Friederike |
author_facet | Xiao, Yin Qureischi, Musga Dietz, Lena Vaeth, Martin Vallabhapurapu, Subrahmanya D. Klein-Hessling, Stefan Klein, Matthias Liang, Chunguang König, Anika Serfling, Edgar Mottok, Anja Bopp, Tobias Rosenwald, Andreas Buttmann, Mathias Berberich, Ingolf Beilhack, Andreas Berberich-Siebelt, Friederike |
author_sort | Xiao, Yin |
collection | PubMed |
description | Posttranslational modification with SUMO is known to regulate the activity of transcription factors, but how SUMOylation of individual proteins might influence immunity is largely unexplored. The NFAT transcription factors play an essential role in antigen receptor-mediated gene regulation. SUMOylation of NFATc1 represses IL-2 in vitro, but its role in T cell–mediated immune responses in vivo is unclear. To this end, we generated a novel transgenic mouse in which SUMO modification of NFATc1 is prevented. Avoidance of NFATc1 SUMOylation ameliorated experimental autoimmune encephalomyelitis as well as graft-versus-host disease. Elevated IL-2 production in T cells promoted T reg expansion and suppressed autoreactive or alloreactive immune responses. Mechanistically, increased IL-2 secretion counteracted IL-17 and IFN-γ expression through STAT5 and Blimp-1 induction. Then, Blimp-1 repressed IL-2 itself, as well as the induced, proliferation-associated survival factor Bcl2A1. Collectively, these data demonstrate that prevention of NFATc1 SUMOylation fine-tunes T cell responses toward lasting tolerance. Thus, targeting NFATc1 SUMOylation presents a novel and promising strategy to treat T cell–mediated inflammatory diseases. |
format | Online Article Text |
id | pubmed-7953626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79536262021-07-04 Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity Xiao, Yin Qureischi, Musga Dietz, Lena Vaeth, Martin Vallabhapurapu, Subrahmanya D. Klein-Hessling, Stefan Klein, Matthias Liang, Chunguang König, Anika Serfling, Edgar Mottok, Anja Bopp, Tobias Rosenwald, Andreas Buttmann, Mathias Berberich, Ingolf Beilhack, Andreas Berberich-Siebelt, Friederike J Exp Med Article Posttranslational modification with SUMO is known to regulate the activity of transcription factors, but how SUMOylation of individual proteins might influence immunity is largely unexplored. The NFAT transcription factors play an essential role in antigen receptor-mediated gene regulation. SUMOylation of NFATc1 represses IL-2 in vitro, but its role in T cell–mediated immune responses in vivo is unclear. To this end, we generated a novel transgenic mouse in which SUMO modification of NFATc1 is prevented. Avoidance of NFATc1 SUMOylation ameliorated experimental autoimmune encephalomyelitis as well as graft-versus-host disease. Elevated IL-2 production in T cells promoted T reg expansion and suppressed autoreactive or alloreactive immune responses. Mechanistically, increased IL-2 secretion counteracted IL-17 and IFN-γ expression through STAT5 and Blimp-1 induction. Then, Blimp-1 repressed IL-2 itself, as well as the induced, proliferation-associated survival factor Bcl2A1. Collectively, these data demonstrate that prevention of NFATc1 SUMOylation fine-tunes T cell responses toward lasting tolerance. Thus, targeting NFATc1 SUMOylation presents a novel and promising strategy to treat T cell–mediated inflammatory diseases. Rockefeller University Press 2020-09-28 /pmc/articles/PMC7953626/ /pubmed/32986812 http://dx.doi.org/10.1084/jem.20181853 Text en © 2020 Xiao et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Xiao, Yin Qureischi, Musga Dietz, Lena Vaeth, Martin Vallabhapurapu, Subrahmanya D. Klein-Hessling, Stefan Klein, Matthias Liang, Chunguang König, Anika Serfling, Edgar Mottok, Anja Bopp, Tobias Rosenwald, Andreas Buttmann, Mathias Berberich, Ingolf Beilhack, Andreas Berberich-Siebelt, Friederike Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title | Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title_full | Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title_fullStr | Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title_full_unstemmed | Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title_short | Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity |
title_sort | lack of nfatc1 sumoylation prevents autoimmunity and alloreactivity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953626/ https://www.ncbi.nlm.nih.gov/pubmed/32986812 http://dx.doi.org/10.1084/jem.20181853 |
work_keys_str_mv | AT xiaoyin lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT qureischimusga lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT dietzlena lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT vaethmartin lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT vallabhapurapusubrahmanyad lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT kleinhesslingstefan lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT kleinmatthias lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT liangchunguang lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT koniganika lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT serflingedgar lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT mottokanja lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT bopptobias lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT rosenwaldandreas lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT buttmannmathias lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT berberichingolf lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT beilhackandreas lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity AT berberichsiebeltfriederike lackofnfatc1sumoylationpreventsautoimmunityandalloreactivity |